APA (7th ed.) Citation

Randall Severance, Howard Schwartz, Ron Dagan, Laurie Connor, Jianing Li, Alison Pedley, . . . for the V114-021. (2022). Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, administered concomitantly with influenza vaccine in healthy adults aged ≥50 years: A randomized phase 3 trial (PNEU-FLU). Taylor & Francis Group.

Chicago Style (17th ed.) Citation

Randall Severance, et al. Safety, Tolerability, and Immunogenicity of V114, a 15-valent Pneumococcal Conjugate Vaccine, Administered Concomitantly with Influenza Vaccine in Healthy Adults Aged ≥50 Years: A Randomized Phase 3 Trial (PNEU-FLU). Taylor & Francis Group, 2022.

MLA (9th ed.) Citation

Randall Severance, et al. Safety, Tolerability, and Immunogenicity of V114, a 15-valent Pneumococcal Conjugate Vaccine, Administered Concomitantly with Influenza Vaccine in Healthy Adults Aged ≥50 Years: A Randomized Phase 3 Trial (PNEU-FLU). Taylor & Francis Group, 2022.